In the second part of the study, the majority of patients were treated with a combination of both immunotherapy-naïve and ant-PD-L1/PD-L1 pretreated, and safety was comparable in both cohorts, with 97% of the immunotherapy-naïve population experiencing any AE (most frequently pyrexia and hypoalbuminemia). The gene discussed is CD274; the disease is Fever.